Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

These findings are consistent with the mechanism of action of spartalizumab and with data reported for inhibitors of PD-1 in other indications. 11 In summary, spartalizumab demonstrated promising ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune ... tumor responses achieved with PD-1/PD-L1 blockade alone.

With its combined immune and antiangiogenic mechanisms, ivonescimab offers a promising new ... Phase III success in lung cancer and its second head-to-head win over a PD-1 inhibitor.1 Currently, the ...